ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286)

Jens Hoeppner(Universität Hamburg), J. R. Siewert(Technical University of Munich), Torben Glatz(University of Freiburg), Florian Lordick(Leipzig University), Peter Bronsert(University of Freiburg), Claudia Schmoor(University Medical Center Freiburg), Thomas Brunner(Medical University of Graz), Dietmar Lorenz(Sana Klinikum Offenbach), Nadine Röthling(University Medical Center Freiburg), Ulrich T. Hopt(University of Freiburg), Christian Ell(Sana Klinikum Offenbach)
BMC Cancer
July 19, 2016
10.1186/s12885-016-2564-y
Cited by 352

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
|The Lancet|2010|7.3k
Gastric cancer
|The Lancet|2020|4.8k
Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2022|1.4k
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
|Journal of Clinical Oncology|2020|1.2k
Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2016|1.1k